Digest Network Come funziona
Network
/
Società
In
Non verificato

Incyte

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

77 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
Fonte
Incyte
Emittente
Business Wire
1.00
0
01/12/2025
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
Fonte
Incyte
Emittente
Business Wire
1.00
0
19/11/2025
Eventi
Finanza
Biotecnologia
Farmaceutica
Salute
Incyte to Present at Upcoming Investor Conferences
Fonte
Incyte
Emittente
Business Wire
1.00
0
17/11/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
Fonte
Incyte
Emittente
Business Wire
1.00
0
06/11/2025
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
Fonte
Incyte
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Eventi
Industria
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
Fonte
Incyte
Emittente
Business Wire
1.00
0
30/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Web e Social Network
Incyte to Present at Upcoming Investor Conferences
Fonte
Incyte
Emittente
Business Wire
1.00
0
28/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
Fonte
Incyte
Emittente
Business Wire
1.00
0
25/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Eventi
Industria
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
Fonte
Incyte
Emittente
Business Wire
1.00
0
12/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Industria
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
Fonte
Incyte
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0